Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · IEX Real-Time Price · USD
1.055
+0.005 (0.47%)
May 3, 2024, 11:24 AM EDT - Market open
Oragenics Revenue
In the year 2023, Oragenics had annual revenue of $37.65K, a decrease of -71.37%.
Revenue (ttm)
$37.65K
Revenue Growth
-71.37%
P/S Ratio
124.95
Revenue / Employee
$7,531
Employees
5
Market Cap
4.79M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 37.65K | -93.87K | -71.37% |
Dec 31, 2022 | 131.52K | 44.53K | 51.20% |
Dec 31, 2021 | 86.99K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 939.93K | -92.31K | -8.94% |
Dec 31, 2013 | 1.03M | -299.53K | -22.49% |
Dec 31, 2012 | 1.33M | -112.68K | -7.80% |
Dec 31, 2011 | 1.44M | 135.54K | 10.35% |
Dec 31, 2010 | 1.31M | 667.63K | 104.11% |
Dec 31, 2009 | 641.29K | 407.75K | 174.59% |
Dec 31, 2008 | 233.54K | 100.45K | 75.48% |
Dec 31, 2007 | 133.09K | 66.91K | 101.11% |
Dec 31, 2006 | 66.18K | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 196.21K | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BIOLASE | 49.16M |
SunLink Health Systems | 39.59M |
Petros Pharmaceuticals | 5.82M |
Aditxt | 645.18K |
Lipella Pharmaceuticals | 449.62K |
Assure Holdings | 255.00K |
OGEN News
- 13 days ago - Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - Business Wire
- 4 weeks ago - Oragenics, Inc. Files 10K and Provides Company Update - Business Wire
- 6 weeks ago - Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion - Business Wire
- 2 months ago - Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion - Business Wire
- 2 months ago - Oragenics Announces Closing of Public Offering - Business Wire
- 2 months ago - Oragenics Announces Pricing of Public Offering - Business Wire
- 2 months ago - Oragenics Announces Proposed Public Offering - Business Wire
- 2 months ago - Oragenics, Inc. Announces Leadership Transition - Business Wire